Tags

Type your tag names separated by a space and hit enter

Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure in elderly patients.

Abstract

American College of Cardiology/American Heart Association class I recommendations for treating patients with heart failure (HF) and abnormal left ventricular ejection fraction are diuretics in patients with fluid retention, an angiotensin-converting enzyme (ACE) inhibitor unless contraindicated, a beta-blocker unless contraindicated, digoxin for the treatment of symptoms of HF, and withdrawal of drugs known to precipitate or aggravate HF such as nonsteroidal anti-inflammatory drugs, calcium channel blockers, and most antiarrhythmic drugs. Class II(a) recommendations for treating HF with abnormal left ventricular ejection fraction are spironolactone in patients with class IV symptoms, preserved renal function, and normal serum potassium; exercise training as an adjunctive approach to improve clinical status in ambulatory patients; an angiotensin receptor blocker in patients who cannot be given an ACE inhibitor because of cough, rash, altered taste sensation, or angioedema; and hydralazine plus nitrates in patients being treated with diuretics, a beta-blocker, and digoxin who cannot be given an ACE inhibitor or an angiotensin receptor blocker because of hypotension or renal insufficiency. Patients with diastolic HF should be treated with cautious use of diuretics and with a beta-blocker. An ACE inhibitor should be added if HF persists or an angiotensin receptor blocker if the patient cannot tolerate an ACE inhibitor because of cough, angioedema, rash, or altered taste sensation. Isosorbide dinitrate plus hydralazine should be added if HF persists. A calcium channel blocker should be added if HF persists. Digoxin should be avoided in diastolic HF if sinus rhythm is present.

Links

  • Aggregator Full Text
  • Authors+Show Affiliations

    Department of Medicine, Cardiology Division, Westchester Medical Center/New York Medical College, Valhalla, NY, USA. WSAronow@aol.com

    Source

    MeSH

    Age Distribution
    Aged
    Cardiac Output, Low
    Diastole
    Female
    Heart Failure
    Humans
    Male
    Middle Aged
    Prognosis
    Sex Distribution
    Survival Rate
    Systole
    United States
    Ventricular Dysfunction, Left

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    12877761

    Citation

    Aronow, Wilbert S.. "Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure in Elderly Patients." Heart Disease (Hagerstown, Md.), vol. 5, no. 4, 2003, pp. 279-94.
    Aronow WS. Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure in elderly patients. Heart Dis. 2003;5(4):279-94.
    Aronow, W. S. (2003). Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure in elderly patients. Heart Disease (Hagerstown, Md.), 5(4), pp. 279-94.
    Aronow WS. Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure in Elderly Patients. Heart Dis. 2003;5(4):279-94. PubMed PMID: 12877761.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure in elderly patients. A1 - Aronow,Wilbert S, PY - 2003/7/25/pubmed PY - 2003/10/4/medline PY - 2003/7/25/entrez SP - 279 EP - 94 JF - Heart disease (Hagerstown, Md.) JO - Heart Dis VL - 5 IS - 4 N2 - American College of Cardiology/American Heart Association class I recommendations for treating patients with heart failure (HF) and abnormal left ventricular ejection fraction are diuretics in patients with fluid retention, an angiotensin-converting enzyme (ACE) inhibitor unless contraindicated, a beta-blocker unless contraindicated, digoxin for the treatment of symptoms of HF, and withdrawal of drugs known to precipitate or aggravate HF such as nonsteroidal anti-inflammatory drugs, calcium channel blockers, and most antiarrhythmic drugs. Class II(a) recommendations for treating HF with abnormal left ventricular ejection fraction are spironolactone in patients with class IV symptoms, preserved renal function, and normal serum potassium; exercise training as an adjunctive approach to improve clinical status in ambulatory patients; an angiotensin receptor blocker in patients who cannot be given an ACE inhibitor because of cough, rash, altered taste sensation, or angioedema; and hydralazine plus nitrates in patients being treated with diuretics, a beta-blocker, and digoxin who cannot be given an ACE inhibitor or an angiotensin receptor blocker because of hypotension or renal insufficiency. Patients with diastolic HF should be treated with cautious use of diuretics and with a beta-blocker. An ACE inhibitor should be added if HF persists or an angiotensin receptor blocker if the patient cannot tolerate an ACE inhibitor because of cough, angioedema, rash, or altered taste sensation. Isosorbide dinitrate plus hydralazine should be added if HF persists. A calcium channel blocker should be added if HF persists. Digoxin should be avoided in diastolic HF if sinus rhythm is present. SN - 1521-737X UR - https://www.unboundmedicine.com/medline/citation/12877761/Epidemiology_pathophysiology_prognosis_and_treatment_of_systolic_and_diastolic_heart_failure_in_elderly_patients_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=12877761.ui DB - PRIME DP - Unbound Medicine ER -